Rutika Mehta
Overview
Explore the profile of Rutika Mehta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mehta R, Sinnamon A, Dam A, Walko C, Palm R, Barton L, et al.
CA Cancer J Clin
. 2023 Oct;
74(2):123-131.
PMID: 37849051
No abstract available.
12.
Sinnamon A, Mehta R, Saeed S, Lauwers G, Palm R, Frakes J, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686650
Neoadjuvant chemoradiation with esophagectomy is standard management for locally advanced esophageal adenocarcinoma. Induction chemotherapy with a tailored approach to chemoradiation based on metabolic response to therapy on PET was explored...
13.
Shariff B, Mehta R
Chin Clin Oncol
. 2023 Jun;
12(3):24.
PMID: 37303220
In the last two decades, the incidence of gastroesophageal junction (GEJ) adenocarcinomas (AC) has increased, in part due to the increasing prevalence of obesity and untreated gastroesophageal reflux disease (GERD)....
14.
Mehta R, Liepa A, Zheng S, Chatterjee A
Curr Oncol
. 2023 Feb;
30(2):1869-1881.
PMID: 36826106
The decision to treat advanced gastroesophageal cancers (GECs) with targeted therapy and immunotherapy is based on key biomarker expression (human epidermal growth factor receptor 2 (HER2), programmed cell death-ligand 1...
15.
Sinnamon A, Savoldy M, Mehta R, Dineen S, Pena L, Lauwers G, et al.
Ann Surg Oncol
. 2023 Feb;
30(6):3580-3589.
PMID: 36765008
Background: Pre-/perioperative chemotherapy is well-established for management of locoregional gastric cancer (LRGC). The American Joint Committee on Cancer advocates histopathologic assessment of tumor regression grade (TRG) but does not endorse...
16.
Shah M, Kennedy E, Alarcon-Rozas A, Alcindor T, Bartley A, Malowany A, et al.
J Clin Oncol
. 2023 Jan;
41(7):1470-1491.
PMID: 36603169
Purpose: To develop recommendations involving targeted therapies for patients with advanced gastroesophageal cancer. Methods: The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of...
17.
18.
Pointer Jr D, McDonald J, Naffouje S, Mehta R, Fleming J, Fontaine J, et al.
J Surg Oncol
. 2022 May;
126(3):465-478.
PMID: 35578777
Background And Objectives: The gold standard for locoregional esophageal cancer (LEC) treatment includes preoperative chemoradiation and surgical resection, with possible perioperative or adjuvant systemic therapy. With few data associating histologic...
19.
Kim R, Kovari B, Martinez M, Xie H, Sahin I, Mehta R, et al.
Eur J Cancer
. 2022 May;
169:93-102.
PMID: 35526308
Aim: In contrast to mismatch repair deficient (dMMR) colorectal cancer (CRC), mismatch repair proficient (pMMR) CRC is usually unresponsive to anti-PD-1 immunotherapy. Recent preclinical data suggest that regorafenib may enhance...
20.
Wood A, Zhang Y, Mo Q, Cen L, Fontaine J, Hoffe S, et al.
Oncologist
. 2022 Apr;
27(4):307-313.
PMID: 35380714
Background: Gastric cancer (GC) and gastroesophageal junction adenocarcinomas (GEJ) are molecularly diverse. TP53 is the most frequently altered gene with approximately 50% of patients harboring mutations. This qualitative study describes...